𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Controlled study of decision-making and cognitive impairment in Parkinson's disease

✍ Scribed by Javier Pagonabarraga; Carmen García-Sánchez; Gisela Llebaria; Berta Pascual-Sedano; Alexandre Gironell; Jaime Kulisevsky

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
113 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Impulse control disorders (ICD) related to reward‐processing dysfunction have been reported in Parkinson's disease (PD). The relationship between clinical markers of limbic dysfunction with demographic variables and cognitive status of PD is incompletely known. Our objective was to further characterize the relationship between limbic and cognitive dysfunction in a representative sample of nondemented PD patients without antecedents of ICD, as assessed by a risk‐taking test of decision‐making and a comprehensive neuropsychological battery. Prospective, controlled study of 35 nondemented PD patients and 31 matched controls who received the Iowa gambling task (IGT), the Mattis Dementia Rating Scale (MDRS) and verbal fluencies for global cognitive function, the Stroop and digit span tests for executive function, and the Rey Auditory Verbal Learning Test for memory. Compared to controls, PD patients performed significantly worse on the IGT. No clear relationship with demographic variables including dopaminergic treatment and motor response to levodopa (stable or fluctuating) emerged. Performance on the IGT was not related to executive function. In contrast, an inverse relationship was found between the IGT and memory and global cognitive performance, with patients with the better MDRS and memory scores performing significantly worse on the IGT. Our results confirm subclinical dysfunction of the limbic system in nondemented PD patients. Although impaired decision‐making appears unrelated to executive dysfunction, patients with the better cognitive status appears more prone to assume risky behaviors. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Medical decision-making capacity in cogn
Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia
✍ Roy C. Martin; Ozioma C. Okonkwo; Joni Hill; H. Randall Griffith; Kristen Triebe 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## Abstract Little is currently known about the higher order functional skills of patients with Parkinson disease and cognitive impairment. Medical decision‐making capacity (MDC) was assessed in patients with Parkinson's disease (PD) with cognitive impairment and dementia. Participants were 16 pati

MRI and cognitive impairment in Parkinso
MRI and cognitive impairment in Parkinson's disease
✍ Naroa Ibarretxe-Bilbao; Eduardo Tolosa; Carme Junque; Maria-Jose Marti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Patients with Parkinson's disease (PD) may present impairment in cognitive functions even at early stages of the disease. When compared with the general population, their risk of dementia is five to six times higher. Recent investigations using structural MRI have shown that dementia in

Cognitive impairment and dementia in Par
Cognitive impairment and dementia in Parkinson's disease
✍ Karen Marder 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based o

Randomized placebo-controlled trial of d
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
✍ Iracema Leroi; Jason Brandt; Stephen G. Reich; Constantine G. Lyketsos; Stephen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). ## Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients rec

Cognitive impairment in nondemented Park
Cognitive impairment in nondemented Parkinson's disease
✍ Paolo Barone; Dag Aarsland; David Burn; Murat Emre; Jaime Kulisevsky; Daniel Wei 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## Abstract A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools